- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02818738
Efficiency of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive Nephrotic Syndrome in Children (NEPHROVIR3)
A Multicenter, Randomised, Double-blind Placebo-controlled Trial Assessing the Efficiency of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive Nephrotic Syndrome in Children.
Study Overview
Status
Intervention / Treatment
Detailed Description
Introduction (INS) is likely a primal immune disorder. Initial treatment relies on steroid therapy. NS is sensitive to steroid in more than 90% of cases, with an excellent renal prognosis. Nevertheless, 80% of patients with steroid sensitive NS do relapse, 60% within the first year. 2/3 of them will experience steroid dependency, with a long lasting relapsing course. These patients require further immunosuppressive drugs as steroid sparing agents, such as mycophenolate, cyclophosphamide, calcineurin inhibitors or rituximab. Morbidity is high and related both to the duration of the disease, sometimes until adulthood, and to treatments side effects.
Levamisole is an immunomodulator that has been used for more than thirty years in the treatment of steroid-dependent or frequently relapsing NS. Its major advantages are its immunomodulatory action and lower and reversible toxicity.
Exact physiopathology of both INS and levamisole action remain unknown. Nevertheless, we make the hypothesis that very early treatment with levamisole may enhance its efficiency and modify the disease's course.
This is the first trial to assess the efficiency of levamisole in increasing duration of remission after the first manifestation of INS.
Design :
- A multicenter, double-blind, placebo-controlled, randomised clinical trial.
- 38 centers participate to the recruitment : 3 Pediatric Nephrology units and 35 General Pediatric units.
- 20 centers participate to the randomized phase.
Sample size :
156 patients, 78 in each group
Treatment groups :
- Levamisole Hydrochloride Dosage : 5, 10, 25 et 50mg. Dosage form : oral tablets Posology : 2.5 mg/kg on alternate days maximum 150mg. Treatment duration : 6 months
- placebo : matching verum
Assessment :
Study visits at inclusion, M1 (randomisation), M3, M6, M9, M12. Supplementary visit if relapse occurs.
Statistical procedure Analysis of efficiency will be performed on intention to treat population. Analysis of tolerance will be performed on randomized patients who have received at least one dose of treatment.
No intermediary analysis is planned.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75019
- Hôpital Robert Debré
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 24 months < age < 16 years
- Diagnosis of first manifestation of INS defined by:
- hypoalbuminemia < 25g/l, proteinuria > 0.20 g/mmol of urinary creatinine
- normal C3 fraction of complement
- Use of mechanical contraception for patients of reproductive age throughout the research period
- Beneficiary of a social protection scheme (except AME)
- Written informed consent from one of both parents
- Ability to realise follow-up in full
Exclusion Criteria:
- Anteriority of INS
- Pregnancy, breast feeding or planned pregnancy during the study
- Malignant pathology (antecedent or ongoing), diabetes, liver disease
- Hypersensitivity to levamisole or its excipients (lactose)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Levamisole Hydrochloride
Dosage : 5, 10, 25 et 50mg.
Dosage form : oral tablets, coated and non dividable for taste-masking Posology : 2.5 mg/kg on alternate days maximum 150mg.
Treatment duration : 6 months
|
Dosage : 5, 10, 25 et 50 mg.
Dosage form : oral tablets, coated and non dividable for taste-masking Posology : 2.5 mg/kg on alternate days maximum 150mg.
Treatment duration : 6 months
|
Placebo Comparator: Placebo
matching verum
|
matching verum
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients still in remission at 12 months after first flare of INS.
Time Frame: 12 months
|
number of patients who did not relapse compared to the number of patients who had relapsed after first flare of INS.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare within levamisole and placebo groups the duration of remission.
Time Frame: first relapse
|
number of days between the first flare and first relapse or up to the corticodependence level in the event of relapse in the course of decreasing corticosteroid therapy.
|
first relapse
|
Compare within levamisole and placebo groups the frequency and level of steroid dependency
Time Frame: 12 months
|
Proportion of corticodependent patients and level of steroid dependency
|
12 months
|
Compare within levamisole and placebo groups the treatment tolerance
Time Frame: 12 months
|
Frequency of adverse events apparition and frequency of discontinuation of treatment secondary at a adverse event.
|
12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Claire DOSSIER, MD, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Kidney Diseases
- Urologic Diseases
- Disease
- Hypersensitivity
- Syndrome
- Nephrotic Syndrome
- Nephrosis
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antirheumatic Agents
- Immunologic Factors
- Adjuvants, Immunologic
- Antiparasitic Agents
- Antinematodal Agents
- Anthelmintics
- Levamisole
Other Study ID Numbers
- P150904
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on First Manifestation of Steroid Sensitive Nephrotic Syndrome
-
Children's Hospital of Fudan UniversityWithdrawnSteroid-Sensitive Nephrotic SyndromeChina
-
Shaheed Zulfiqar Ali Bhutto Medical UniversityRecruitingSteroid-Sensitive Nephrotic SyndromePakistan
-
Assistance Publique - Hôpitaux de ParisRecruitingSteroid-Dependent Nephrotic Syndrome | Steroid-Sensitive Nephrotic SyndromeFrance
-
Children's Hospital of Fudan UniversityShanghai Children's Hospital; Shanghai Children's Medical Center; Xinhua Hospital... and other collaboratorsNot yet recruitingSteroid-Sensitive Nephrotic SyndromeChina
-
Seoul National University Childrens HospitalUnknownSteroid Resistant Nephrotic Syndrome | Steroid Dependent Nephrotic SyndromeKorea, Republic of
-
Children's Hospital of Fudan UniversityShandong Provincial Hospital; Wuhan Union Hospital, China; Children's Hospital... and other collaboratorsCompletedSteroid-Sensitive Nephrotic SyndromeChina
-
Assiut UniversityUnknownSteroid Dependent and Steroid Resistent Nephrotic Syndrome
-
Nationwide Children's HospitalGenentech, Inc.; Emory University; Children's Healthcare of Atlanta; The NephCure...TerminatedSteroid Dependent Nephrotic Syndrome | Frequent Relapsing Nephrotic SyndromeUnited States
-
Children's Hospital of Fudan UniversityShanghai Children's Hospital; Shanghai Children's Medical Center; Xinhua Hospital...WithdrawnSteroid-Dependent Nephrotic Syndrome | Frequently Relapsing Nephrotic SyndromeChina
-
Rhode Island HospitalUniversity of Minnesota; Mallinckrodt; MedalyticsWithdrawnSteroid-Resistant Nephrotic Syndrome
Clinical Trials on Levamisole Hydrochloride
-
The First Affiliated Hospital of Zhengzhou UniversityFirst Affiliated Hospital of Xinjiang Medical University; Anyang Tumor Hospital and other collaboratorsRecruiting
-
The First Affiliated Hospital of Zhengzhou UniversityAnyang Tumor Hospital; Luoyang Central Hospital; Nanyang Central Hospital; Sanmenxia... and other collaboratorsRecruiting
-
Programme National de Lutte contre l'Onchocercose...Institut de Recherche pour le DeveloppementNot yet recruiting
-
Shengyun LinUnknown
-
Ain Shams UniversityUnknownCoronavirus Disease (COVID-19)Egypt
-
The First Affiliated Hospital of Zhengzhou UniversityUnknown
-
NSABP Foundation IncNational Cancer Institute (NCI); Northern California Cancer CenterCompleted
-
Southwest Oncology GroupNational Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical... and other collaboratorsCompletedColorectal CancerUnited States, Canada, South Africa
-
Institute of Hematology & Blood Diseases HospitalUnknownPathologic Processes | Immune System Diseases | Autoimmune Diseases | Hematologic Diseases | Anemia | Anemia, Hemolytic | Hemolysis | Anemia, Hemolytic, AutoimmuneChina
-
Jianhua ZhouLinkDoc Technology (Beijing) Co. Ltd.RecruitingNephrotic Syndrome in ChildrenChina